Rachel E. Sanborn

机构：Providence Portland Medical Center

发表论文 8 篇 · 总被引 98 次 · h-index 5

代表论文

• Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A (2025 · Journal of Thoracic Oncology · 被引 32)
• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016 · Journal for ImmunoTherapy of Cancer · 被引 17)
• Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study (2025 · Journal of Thoracic Oncology · 被引 16)
• Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report (2025 · Journal of Thoracic Oncology · 被引 14)
• Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study (2025 · Targeted Oncology · 被引 1)
• 1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings (2025)